Bridgeway Capital Management’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Bridgeway Capital Management’s Portfolio SCPS Stock Details SCPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-32,966	Closed	-$14K	–	1468
2022 Q2	$14K	Sell	32,966 -35,000	-51%	-$16.8K	﹤0.01%	1317
2022 Q1	$47K	Sell	67,966 -26,000	-28%	-$25.1K	﹤0.01%	1292
2021 Q4	$154K	Buy	93,966 +23,100	+33%	+$70K	﹤0.01%	1184
2021 Q3	$294K	Buy	70,866 +23,857	+51%	+$123K	0.01%	1161
2021 Q2	$336K	Hold	47,009	–	–	0.01%	1187
2021 Q1	$397K	Buy	+47,009	New	+$492K	0.01%	1161

Other funds holding SCPS

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MRCM

M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Bridgeway Capital Management's SCPS Position: Q3 2022 in Review

Bridgeway Capital Management sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q3 2022, closing a stake of 32,966 shares — an estimated $14K sold.

Bridgeway Capital Management first reported a position in SCPS in Q1 2021 and held it in 6 quarters. The position peaked at $397K in Q1 2021. 15 funds tracked by Wall St. Rank hold SCPS as of Q3 2022.

Bridgeway Capital Management reported no remaining Scopus BioPharma Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Bridgeway Capital Management sold 32,966 Scopus BioPharma Inc. Common Stock shares in Q3 2022, an estimated $14K.
Bridgeway Capital Management first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Bridgeway Capital Management's Scopus BioPharma Inc. Common Stock position peaked at $397K in Q1 2021.
15 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q3 2022.

Based on Bridgeway Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.